Aspirin resistance in neurovascular diseases

Title:

Aspirin resistance in neurovascular diseases
Aspirin resistance in neurovascular diseases

Creator:

Vališ, Martin, Krajíčková, Dagmar, Malý, Jaroslav, Malý, Radovan, Fátorová, Ilona, Vyšata, Oldřich, and Herzig, Roman

Contributor:

Vališ, Martin , 1973-, Krajíčková, Dagmar , 1948-, Malý, Jaroslav , 1946-, Malý, Radovan, Fátorová, Ilona, Vyšata, Oldřich, and Herzig, Roman , 1968-

Identifier:

https://cdk.lib.cas.cz/client/handle/uuid:bmc15030953-2133cf83-8d31-47cb-8f63-462f8da1f28d
uuid:bmc15030953-2133cf83-8d31-47cb-8f63-462f8da1f28d
local:bmc15030953
http://actamedica.lfhk.cuni.cz/
doi: 10.14712/18059694.2015.81
local: bmc15030953

Subject:

staří, Aspirin--farmakologie, cerebrovaskulární poruchy--farmakoterapie, léková rezistence, ženské pohlaví, lidé, mužské pohlaví, inhibitory agregace trombocytů--farmakologie, and prevalence

Type:

model:article, article, Text, časopisecké články, práce podpořená grantem, and TEXT

Format:

print, text, and regular print

Description:

INTRODUCTION: The issue of resistance to antiplatelet therapy has raised many questions in the area of neurovascular diseases. The first objective of this work was to determine the prevalence of aspirin resistance in neurovascular patients with clinical non-responsiveness to aspirin treatment and a high-risk of atherothrombotic complications using two interpretable and independent methods (aggregation and PFA 100). The second objective was to find the correlation between both assays and to evaluate the results in groups at risk for various cerebrovascular diseases. MATERIAL AND METHODS: Laboratory tests of aspirin resistance were performed in 79 patients with clinical non-responsiveness to aspirin treatment suffering from neurovascular diseases. Patients were divided into the two groups: expected low risk for aspirin resistance due to the first manifestation of a neurovascular disease (n = 34) and expected high risk due to the second clinical manifestation of a neurovascular disease (n = 45). RESULTS: The prevalence of aspirin resistance in both groups combined as determined by the PFA-100 and CPG techniques were 50.6% and 17.7%, respectively. No correlation was found between the two techniques. CONCLUSIONS: No significant prevalence of aspirin resistance was demonstrated by either method despite the heterogeneous pathophysiological mechanisms. However, we are presently unable to provide an accurate opinion on the value of laboratory test result or routine monitoring in clinical neurology. and M. Vališ, D. Krajíčková, J. Malý, R. Malý, I. Fátorová, O. Vyšata, R. Herzig

Language:

English

Rights:

http://creativecommons.org/publicdomain/mark/1.0/
policy:public

Relation:

Acta medica (Hradec Králové) Universitas Carolina, Facultas Medica Hradec Králové--MED00010947

Source:

Acta medica (Hradec Králové) | 2014 Volume:57 | Number:4

Harvested from:

CDK

Metadata only:

false

Date:

2014